Lupin gains on re-introducing Methergine oral tablets in US

The company has re-introduced Methergine Oral tablets 0.2mg for the management of PPH

Shares of Lupin were up over 2% at Rs 1,612 on the Bombay Stock Exchange after the company and its US subsidiary, Lupin Pharmaceuticals Inc., announced the re-introduction of Methergine (methylergonovine maleate) Oral tablets 0.2mg in the US.

The drug is dispensed for the prevention and management of postpartum haemorrhage (PPH) and Methergine is the only FDA-approved oral uterotonic and is a preferred oral agent in the management of PPH, according to guidelines issued by the American Congress of Obstetricians and Gynaecologists, the company said in a release.

“The re-introduction of Methergine is a proud moment for Lupin, but also an important moment for expectant mothers  across  the  country  to  feel  confident  in  care  options,”  the released said quoting Paul  McGarty,  President,  Lupin Pharmaceuticals  Inc.
 

The stock opened at Rs 1587 and touched a high of Rs 1,618. At 10:55am, over 607,000 shares were traded on both the stock exchanges.